Dose model for stent-based delivery of a radioactive compound for the treatment of restenosis in coronary arteries.
Radiolabeled drug-eluting stents have been proposed recently as a novel method to potentially reduce restenosis in coronary arteries. A P-32 labeled oligonucleotide (ODN) loaded on a polymer coated stent is slowly released in the arterial wall to deliver a therapeutic dose to the target tissue. However, the relatively low proportion of drugs transferred to the arterial wall (<2%-5% typically) raises questions about the degree to which radiolabeled drugs eluted from the stent can contribute to the total radiation dose delivered to tissues. A three-dimensional diffusion-convection transport model is used to model the transport of a hydrophilic drug released from the surface of a stent to the arterial media. Large drug concentration gradients are observed near the stent struts giving rise to a nonuniform radiation activity distribution for the drug in the tissues as a function of time. A voxel-based kernel convolution method is used to calculate the radiation dose rate resulting from this activity build-up in the arterial wall based on the medical internal radiation dose formalism. Measured residence time for the P-32 ODN in the arterial wall and at the stent surface obtained from animal studies are used to normalize the results in terms of absolute dose to tissue. The results indicate that radiation due to drug eluted from the stent contributes only a small fraction of the total radiation delivered to the arterial wall, the main contribution coming from the activity that remains embedded in the stent coating. For hydrophilic compounds with rapid transit times in arterial tissue and minimal binding interactions, the activity build-up in the arterial wall contributes only a small fraction to the total dose delivered by the P-32 ODN stent. For these compounds, it is concluded that radiolabeled drug-eluting stent will not likely improve the performance of radioactive stents for the treatment of restenosis. Also, variability in the delivery efficacy of drug delivery devices makes accurate dosimetry difficult and the drug washout in the systemic circulatory system may yield an unnecessary activity build-up and dose to healthy organs.
Janicki
Christian
C
McGill University Health Center, Department of Medical Physics, Montreal, Quebec H36 1A4, Canada. cjanicki@medphys.mcgill.ca
Hwang
Chao-Wei
CW
Edelman
Elazer R
ER
D001158:Arteries / Q000473:pathology; D003251:Constriction, Pathologic / Q000628:therapy; D023903:Coronary Restenosis / Q000532:radiotherapy*; D003331:Coronary Vessels / Q000473:pathology*; D004058:Diffusion; D006493:Heparin / Q000737:chemistry; D006801:Humans; D015233:Models, Statistical; D009841:Oligonucleotides / Q000494:pharmacology / Q000627:therapeutic use; D010761:Phosphorus Radioisotopes / Q000494:pharmacology; D011108:Polymers / Q000737:chemistry; D011874:Radiometry; D015607:Stents; D013997:Time Factors
D009841:Oligonucleotides; D010761:Phosphorus Radioisotopes; D011108:Polymers; D006493:Heparin